Natco Pharma Ltd News Today

In a statement, NATCO Pharma stated it is confident of addressing all the observations within the stated time frame.

Here are some of the stocks that may see significant price movement today: United Spirits, Biocon, NATCO Pharma, etc.

Quarterly revenue came in at ₹1,287.3 crore, a 16% YoY increase from ₹1,110.3 crore in Q4 FY24, led by robust performance in key segments.

The drug enhances the flow of blood through the lungs, allowing children with PAH to breathe and improve their ability to engage in physical activity.

The company was ensured that the sale of the land and building did not constitute part of its operational assets so that the sale will, in no way, impact the company's business operations

The revenue for the September quarter rose by 33% to ₹1,371 crore from ₹1,031 crore in the corresponding period last year.

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.

The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.

Natco Pharma disclosed that its subsidiary will invest USD 8 million in eGenesis, acquiring a total of 40,629,761 shares.